APAC Healthcare Weekly (December 21)–Fosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health
Fosun Pharma is acquiring 53% stake in Green Valley. Hansoh inked exclusive license agreement with Glenmark Pharma. Daiichi Sankyo’s Enhertu got...
447 Views
Neuren Pharmaceuticals (NEU AU): Net Profit Doubles in 1H On Daybue Acceleration; Guidance Restated
​Neuren Pharmaceuticals reports strong 1H25 result, doubling net profit with high-teens revenue growth. The company anticipates earning U.S....
339 Views
Neuren Pharmaceuticals (NEU AU): Daybue US Sales and Geography Expansion to Drive Growth
Neuren Pharmaceuticals got confirmation from the FDA for the primary endpoints for its planned Phase 3 pivotal clinical trial of NNZ-2591 in Phelan...
708 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
​Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
769 Views
APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life
China published 2025 NRDL, adding 114 new drugs. Fosun Pharma inked outlicensing deal with Pfizer for obesity drug candidate. PeptiDream achieved...
525 Views